Valuation: Cerenome, Inc.

Market Cap 21.2M 18.31M 17.23M 15.66M 29.45M 2.03B 29.88M 202M 79.2M 1.02B 79.6M 77.87M 3.38B P/E 2026 *
-0.85x
P/E 2027 * -1.29x
Enterprise Value 21.2M 18.31M 17.23M 15.66M 29.45M 2.03B 29.88M 202M 79.2M 1.02B 79.6M 77.87M 3.38B EV / Sales 2026 *
3.52x
EV / Sales 2027 * 1.11x
Free-Float
98.2%
Yield 2026 *
-
Yield 2027 * -
1 day-3.75%
1 week-19.58%
Current month-20.41%
1 month-17.65%
3 months-47.26%
6 months-56.47%
Current year-75.95%
1 week 3
Extreme 3
3.92
1 month 3
Extreme 3
4.16
Current year 2.9
Extreme 2.9
15.32
1 year 2.9
Extreme 2.9
23.42
3 years 2.9
Extreme 2.9
80.25
5 years 2.9
Extreme 2.9
862.5
10 years 2.9
Extreme 2.9
429,377.68
Manager TitleAgeSince
Chief Executive Officer 64 02/04/2014
Director of Finance/CFO 52 06/02/2020
Chief Tech/Sci/R&D Officer - 21/10/2025
Director TitleAgeSince
Director/Board Member 64 01/10/2002
Chairman 77 25/01/2018
Director/Board Member 66 01/01/2020
Date Insider Type Main position Quantity % Market Cap.
1/7/26 Fiscal year

Director

1,844 0.0269%
1/7/26 Fiscal year

Chief Financial Officer

5,970 0.0870%
1/7/26 Fiscal year

Director

1,844 0.0269%
Change 5-day change 1-year change 3-year change Capi.($)
-3.75%-19.58%-77.02%-94.71% 21.2M
+1.06%+0.88%+1.96%+21.56% 48.63B
+1.89%+5.08%+492.59%+629.24% 46.3B
+1.83%+2.75%+15.61%+91.22% 41.97B
-0.50%-1.56%+24.67%+12.17% 39.51B
-2.74%-7.13%+18.72%+49.04% 31.75B
-1.14%-2.51%+27.52%+136.42% 16.48B
+0.59%-2.25% - - 16.34B
+0.17%+0.26%+2.92%+29.80% 14B
-2.60%-1.00%+77.85%+40.37% 13.33B
Average -0.74%-2.82%+64.98%+101.68% 26.83B
Weighted average by Cap. -0.13%-0.43%+105.78%+155.76%

Financials

2026 *2027 *
Net sales 6.02M 5.2M 4.89M 4.45M 8.37M 577M 8.49M 57.41M 22.5M 289M 22.61M 22.12M 961M 19.14M 16.53M 15.55M 14.14M 26.59M 1.83B 26.98M 182M 71.51M 917M 71.86M 70.3M 3.06B
Net income -34.22M -29.55M -27.8M -25.27M -47.53M -3.28B -48.23M -326M -128M -1.64B -128M -126M -5.46B -18.45M -15.94M -15M -13.63M -25.64M -1.77B -26.01M -176M -68.94M -884M -69.29M -67.78M -2.95B
Net Debt - -
Logo Cerenome, Inc.
Plus Therapeutics, Inc. is a healthcare company developing and commercializing precision diagnostics and targeted radiopharmaceuticals for central nervous system (CNS) cancers. Its subsidiary CNSide Diagnostics, LLC, develops and commercializes proprietary laboratory-developed tests, such as CNSide, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. Its lead radiotherapeutic candidate, REYOBIQ (rhenium (186Re) obisbemeda), is designed specifically for CNS cancers including GBM, LM, and pediatric brain cancers (PBC) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery (CED) and intraventricular brain (Ommaya reservoir) catheters. Its radiotherapeutic candidate, Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere, is designed to treat many solid organ cancers, including primary and secondary liver cancers by intra-arterial injections.
Employees
28
Date Price Change Volume
18/08/26 US$3.080 -3.75% 92,586
17/08/26 US$3.200 -13.04% 272,032
14/08/26 US$3.680 -0.54% 109,031
13/08/26 US$3.700 0.00% 62,111
12/08/26 US$3.700 -3.39% 65,901
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
3.080USD
Average target price
36.00USD
Spread / Average Target
+1,068.83%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CNSY Stock